Navigation Links
PPTA Praises Legislation That Protects the Treatment of Rare Diseases
Date:7/29/2011

ANNAPOLIS, Md., July 29, 2011 /PRNewswire-USNewswire/ -- The Plasma Protein Therapeutics Association (PPTA) applauds the introduction of bipartisan legislation, the Preserving Access to Orphan Drugs Act (H.R. 2672) and (S. 1423), which will safeguard the development of drugs and therapies that treat patients with rare diseases by eliminating barriers to innovation.

"The majority of patients who rely on plasma protein therapies are coping with a very rare disease for which no alternative treatment exists," said Julie Birkofer, senior vice president, North America, PPTA. "This legislation preserves access to therapies and drugs for rare disease patients and helps to ensure that research and development into new therapies for orphan diseases continues to be encouraged and remains unencumbered."

"The Association recognizes the commitment to preserving orphan drug development demonstrated by Representative Jim Gerlach (R-Pa), who introduced H.R. 2672 with lead cosponsor Representative Jason Altmire (D-PA) and Senator Patrick Toomey (R-PA), who introduced the companion bill, S. 1423, with lead cosponsors Sens. Robert Casey (D-PA) and Ron Wyden (D-OR)," Birkofer said.

Under the current law, most plasma protein therapies, despite being approved for marketing by the U.S. Food and Drug Administration (FDA) solely for the treatment of one or more rare disease or condition, would not qualify for the orphan drug exclusion from the annual pharmaceutical fee. In the U.S., a rare disease or condition is generally defined as one affecting less than 200,000 persons. H.R. 2672 and S. 1423 modify the law to ensure that manufacturers can exclude the sales of all drugs and therapies that are FDA-indicated solely for the treatment of one or more rare disease from their annual fee liability. The legislation is bipartisan and budget neutral.

Plasma protein therapies, which include plasma-derived therapies and recombinant blood clotting factors (a biotechnology product), are biological products that are not interchangeable, and no generics or substitutions exist. These unique therapies are used every day to treat people with bleeding disorders including hemophilia, which causes painful internal bleeding and debilitating joint damage; primary immunodeficiency diseases, which render the body defenseless from even the most common infections, often leading to pneumonia and other serious illnesses; and alpha-1 antitrypsin deficiency, also known as genetic chronic obstructive pulmonary disease (COPD), which severely damages the liver and lungs. Additionally, a plasma protein therapy, albumin, is used in critical care settings, when treating severe trauma, burns and during major surgery.

The Plasma Protein Therapeutics Association (PPTA) represents the world's leading manufacturers of plasma-derived and recombinant biological therapies, collectively known as plasma protein therapies. These critical therapies are infused or injected by more than 1 million people worldwide to treat a variety of rare, life threatening diseases and serious medical conditions. PPTA members produce in excess of 80 percent of the plasma protein therapies used in the United States today. PPTA is a global trade association that administers international, voluntary standards programs to help ensure the highest quality and safety of plasma protein therapies and the plasma collected to manufacture them. Additionally, PPTA works in partnership with the patient community and consumer advocates to help ensure continued access to lifesaving plasma protein therapies.


'/>"/>
SOURCE Plasma Protein Therapeutics Association (PPTA)
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. AMERIGROUP Praises Expansion of State Childrens Health Insurance Program (SCHIP)
2. CA PPG Says California Physicians Contradict Themselves Regarding Employment Legislation
3. Regional Biotech Association Warns Legislation Would Make VT Least Friendly State in Nation for Biotechnology and Life Sciences
4. Regional Biotech Association Warns Vermont Legislation Could Have Profound Negative Impact
5. Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions
6. Hospira Supports Newly Introduced Biogenerics Legislation
7. Teva Applauds Historic Biotech Competition Legislation
8. NOVAVAX Virus-Like Particle Vaccine Protects Against 2009 Pandemic H1N1 Influenza Virus
9. Spectros Corporation Protects Its Cool White LED Spectroscopy Technology Against Alleged Infringement by Thermo Fisher Scientific
10. Germgards Ultra-Fast Hand Hygiene Solution Protects Against Deadly MRSA, C difficile, and Influenza Virus
11. Pathway for Biosimilars Act Protects Patients, Promotes Competition, Preserves Innovation and Creates Quality Jobs, Lilly Says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 29, 2016 , ... Proove Biosciences, Inc ., the ... launch of the Proove Health Foundation . The Foundation is a non-profit ... use of personalized medicine for tackling the nation’s most-pressing healthcare epidemics. As part ...
(Date:4/29/2016)... ... ... Intelligent Implant Systems announced today that the two-level components for the Revolution™ Spinal System ... These components expand the capabilities of the system and allow Revolution™ to be utilized ... the company has seen significant sales growth in 1Q 2016, and the system is ...
(Date:4/28/2016)... ... April 28, 2016 , ... Next ... a talk on its first-in-class technologies for tissue stem cell counting and expansion ... RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome Engineering in Burlington, Massachusetts. , The ...
(Date:4/27/2016)... ... April 27, 2016 , ... The Pittcon Organizing Committee is pleased to ... been a volunteer member of Committee since 1987. Since then, he has served in ... treasurer and was chairman for both the program and exposition committees. In his professional ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):